Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.

Antiviral therapy - 1 Jan 2007

Marcelin Anne-Genevieve, Flandre Philippe, de Mendoza Carmen, Roquebert Benedicte, Peytavin Gilles, Valer Luisa, Wirden Marc, Abbas Sarah, Katlama Christine, Soriano Vincent, Calvez Vincent

Abstract excerpt

OBJECTIVE: To identify a genotypic score for resistance to saquinavir boosted with ritonavir (SQV/r; 1,000/100 mg twice daily)-based regimens in protease inhibitor (PI)-experienced patients. METHODS: One-hundred and fifty-one PI-experienced patients receiving a SOV/r-containing regimen were enrolled retrospectively. The virological response (VR) was defined as the decrease in HIV RNA at months 3-5. The effect of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Multiple, Viral
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to France

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Ritonavir

Share to Saquinavir

Share to Treatment Failure

Source

Identifiers

PMID: 17503666

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.PMID 17503666Read ↗

Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.Semantic proximity Read ↗

Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.Semantic proximity Read ↗

Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.Semantic proximity Read ↗

Analysis of genotypic and phenotypic clinical cut-off levels for ritonavir-boosted saquinavir.Semantic proximity Read ↗

Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients.Semantic proximity Read ↗

HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed.Semantic proximity Read ↗

Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials.Semantic proximity Read ↗

Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients.Semantic proximity Read ↗

Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens.Semantic proximity Read ↗

Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.Semantic proximity Read ↗

Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.Semantic proximity Read ↗

Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.